Increasing the dosing interval of dupilumab in patients with severe asthma and chronic rhinosinusitis with nasal polyps

To the Editor, we present a series of five patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in whom the dosing interval of dupilumab was extended from every 2 weeks to every 4 weeks while maintaining clinical stability.Severe eosinophilic asthma responds effectively to biologic therapies [1], with several options available.Although no specific studies have examined the gradual extension of dupilumab dosing intervals in patients with asthma and CRSwNP, the drug has demonstrated efficacy in reducing nasal polyposis [2], decreasing exacerbations [3], and improving lung function [4].However, evidence regarding the extension of dosing intervals in patients with favorable clinical outcomes remains limited.